NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
The appointment follows NewcelX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear regulatory pathway toward clinical trials
The appointment follows NewcelX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear regulatory pathway toward clinical trials
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.